Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in
Jose Baselga
JOSE BASELGA, Vall d’Hebron Hospital, BarcelonaRAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and so Derek Thorne got the details fromJose Baselgaof Vall d’Hebron Hospital in Barcelona.
